Biochemical correction of very long-chain acyl-coa dehydrogenase deficiency following adeno-associated virus gene therapy

J. Lawrence Merritt, Tien Nguyen, Jan Daniels, Dietrich Matern, David B. Schowalter

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

We report the development of a gene replacement strategy for very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency. VLCAD is a mitochondrial enzyme involved in fatty acid β-oxidation, a key step in energy production during times of fasting or stress. Deficiency of VLCAD classically presents as hepatic dysfunction, hypoglycemia, cardiomyopathy, rhabdomyolysis, and/or sudden death. While dietary therapy for VLCAD deficiency has proven beneficial in preventing some symptoms, a risk of metabolic catastrophic decompensation remains throughout life during times of increased energy demand. We designed a recombinant adeno-associated virus (AAV) expressing the human VLCAD gene (AAV8-hVLCAD). To demonstrate its in vivo activity, AAV8-hVLCAD was administered via the tail vein to VLCAD-knockout mice. A reduction in accumulated serum long-chain acylcarnitines and increased fasting tolerance judged on blood glucose concentrations were observed as of 11 days postinjections through >100 days. Western analysis of liver, skeletal muscle, and heart extracts using PEP1 anti-hVLCAD antibody revealed short-term hVLCAD expression in the liver and muscle and longer-term expression in heart. This demonstrates the ability of human VLCAD to correct the biochemical phenotype of VLCAD-deficient mice.

Original languageEnglish (US)
Pages (from-to)425-429
Number of pages5
JournalMolecular Therapy
Volume17
Issue number3
DOIs
StatePublished - 2009

Fingerprint

human ACADVL protein
Long-Chain Acyl-CoA Dehydrogenase
Dependovirus
Genetic Therapy
Liver
Fasting
Rhabdomyolysis
Aptitude
Sudden Death
Cardiomyopathies
Hypoglycemia
Knockout Mice
Genes
Blood Glucose
Tail
Anti-Idiotypic Antibodies
Veins
Skeletal Muscle
Fatty Acids
Phenotype

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Genetics
  • Drug Discovery
  • Pharmacology

Cite this

Biochemical correction of very long-chain acyl-coa dehydrogenase deficiency following adeno-associated virus gene therapy. / Merritt, J. Lawrence; Nguyen, Tien; Daniels, Jan; Matern, Dietrich; Schowalter, David B.

In: Molecular Therapy, Vol. 17, No. 3, 2009, p. 425-429.

Research output: Contribution to journalArticle

Merritt, J. Lawrence ; Nguyen, Tien ; Daniels, Jan ; Matern, Dietrich ; Schowalter, David B. / Biochemical correction of very long-chain acyl-coa dehydrogenase deficiency following adeno-associated virus gene therapy. In: Molecular Therapy. 2009 ; Vol. 17, No. 3. pp. 425-429.
@article{eb7e472aa3f9426295489c14921698df,
title = "Biochemical correction of very long-chain acyl-coa dehydrogenase deficiency following adeno-associated virus gene therapy",
abstract = "We report the development of a gene replacement strategy for very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency. VLCAD is a mitochondrial enzyme involved in fatty acid β-oxidation, a key step in energy production during times of fasting or stress. Deficiency of VLCAD classically presents as hepatic dysfunction, hypoglycemia, cardiomyopathy, rhabdomyolysis, and/or sudden death. While dietary therapy for VLCAD deficiency has proven beneficial in preventing some symptoms, a risk of metabolic catastrophic decompensation remains throughout life during times of increased energy demand. We designed a recombinant adeno-associated virus (AAV) expressing the human VLCAD gene (AAV8-hVLCAD). To demonstrate its in vivo activity, AAV8-hVLCAD was administered via the tail vein to VLCAD-knockout mice. A reduction in accumulated serum long-chain acylcarnitines and increased fasting tolerance judged on blood glucose concentrations were observed as of 11 days postinjections through >100 days. Western analysis of liver, skeletal muscle, and heart extracts using PEP1 anti-hVLCAD antibody revealed short-term hVLCAD expression in the liver and muscle and longer-term expression in heart. This demonstrates the ability of human VLCAD to correct the biochemical phenotype of VLCAD-deficient mice.",
author = "Merritt, {J. Lawrence} and Tien Nguyen and Jan Daniels and Dietrich Matern and Schowalter, {David B.}",
year = "2009",
doi = "10.1038/mt.2008.295",
language = "English (US)",
volume = "17",
pages = "425--429",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Biochemical correction of very long-chain acyl-coa dehydrogenase deficiency following adeno-associated virus gene therapy

AU - Merritt, J. Lawrence

AU - Nguyen, Tien

AU - Daniels, Jan

AU - Matern, Dietrich

AU - Schowalter, David B.

PY - 2009

Y1 - 2009

N2 - We report the development of a gene replacement strategy for very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency. VLCAD is a mitochondrial enzyme involved in fatty acid β-oxidation, a key step in energy production during times of fasting or stress. Deficiency of VLCAD classically presents as hepatic dysfunction, hypoglycemia, cardiomyopathy, rhabdomyolysis, and/or sudden death. While dietary therapy for VLCAD deficiency has proven beneficial in preventing some symptoms, a risk of metabolic catastrophic decompensation remains throughout life during times of increased energy demand. We designed a recombinant adeno-associated virus (AAV) expressing the human VLCAD gene (AAV8-hVLCAD). To demonstrate its in vivo activity, AAV8-hVLCAD was administered via the tail vein to VLCAD-knockout mice. A reduction in accumulated serum long-chain acylcarnitines and increased fasting tolerance judged on blood glucose concentrations were observed as of 11 days postinjections through >100 days. Western analysis of liver, skeletal muscle, and heart extracts using PEP1 anti-hVLCAD antibody revealed short-term hVLCAD expression in the liver and muscle and longer-term expression in heart. This demonstrates the ability of human VLCAD to correct the biochemical phenotype of VLCAD-deficient mice.

AB - We report the development of a gene replacement strategy for very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency. VLCAD is a mitochondrial enzyme involved in fatty acid β-oxidation, a key step in energy production during times of fasting or stress. Deficiency of VLCAD classically presents as hepatic dysfunction, hypoglycemia, cardiomyopathy, rhabdomyolysis, and/or sudden death. While dietary therapy for VLCAD deficiency has proven beneficial in preventing some symptoms, a risk of metabolic catastrophic decompensation remains throughout life during times of increased energy demand. We designed a recombinant adeno-associated virus (AAV) expressing the human VLCAD gene (AAV8-hVLCAD). To demonstrate its in vivo activity, AAV8-hVLCAD was administered via the tail vein to VLCAD-knockout mice. A reduction in accumulated serum long-chain acylcarnitines and increased fasting tolerance judged on blood glucose concentrations were observed as of 11 days postinjections through >100 days. Western analysis of liver, skeletal muscle, and heart extracts using PEP1 anti-hVLCAD antibody revealed short-term hVLCAD expression in the liver and muscle and longer-term expression in heart. This demonstrates the ability of human VLCAD to correct the biochemical phenotype of VLCAD-deficient mice.

UR - http://www.scopus.com/inward/record.url?scp=61649125586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61649125586&partnerID=8YFLogxK

U2 - 10.1038/mt.2008.295

DO - 10.1038/mt.2008.295

M3 - Article

C2 - 19156135

AN - SCOPUS:61649125586

VL - 17

SP - 425

EP - 429

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 3

ER -